ERBB2 and cancer: CMTC was also found to be an independent predictor of relapse-free survival when we controlled for receptor status (ER- versus ER+ cancers, and non-HER2+/TN versus HER2+/TN cancers) as shown in Figure S3 in Additional file 2.